Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (391)	1/11/1999 4:28:00 PM
From: Douglas Nordgren	Read Replies (1) \| Respond to of 4974

LKST H&Q Highlights: biz.yahoo.com Monday January 11, 3:29 pm Eastern Time Company Press Release SOURCE: LeukoSite, Inc. LeukoSite, Inc. Addresses Hambrecht & Quist's 17th Annual Health Care Conference HAMBRECHT & QUIST HEALTH CARE '99 CONFERENCE, SAN FRANCISCO, Jan. 11, /PRNewswire/ -- Christopher Mirabelli, Ph.D., Chairman and CEO of LeukoSite, Inc. (Nasdaq: LKST - news) presented today at the Hambrecht & Quist Annual Health Care Conference. LeukoSite, Inc., headquartered in Cambridge, Massachusetts, is a biotechnology company developing novel drugs that selectively block the disease-promoting actions of leukocytes (white blood cells). The Company's programs capitalize on advanced expertise in leukocyte biology and on a proprietary approach to rapidly advancing biological insights into both antibody-based therapeutics and small molecule drugs. LeukoSite has three monoclonal antibody drug candidates in clinical trials and nine small molecule discovery programs in the areas of cancer, as well as autoimmune, inflammatory and other immune related diseases. In his presentation, Dr. Mirabelli gave an overview of the Company, its products and its strategy moving forward. Below are some key points of the presentation. Leukocytes perform a wide range of beneficial functions, including ridding the body of infection and repairing tissue damage. However, inappropriate leukocyte recruitment, activation or proliferation has been found to play a role in a broad spectrum of diseases. The ability of leukocytes to home to specific sites in the body is highly regulated by interactions between molecules on the cell surface of leukocytes (chemokine receptors and integrins) and tissue-specific molecules (chemokines and cell adhesion molecules). LeukoSite's expertise in leukocyte biology is the critical starting point in the development of selective therapeutics for the treatment of immune diseases. The Company's technology platform and strategy focus on rapid target identification, validation and early drug discovery. This approach rapidly yields both monoclonal antibody and small molecule therapeutics. Therapeutics that selectively target disease-promoting cells do not broadly suppress the immune system and yield fewer side effects and greater efficacy. LeukoSite has three monoclonal antibodies in clinical development, including CAMPATH® in pivotal studies in patients with refractory chronic lymphocytic leukemia; LDP-02 in Phase II studies in patients with inflammatory bowel disease; and LDP-01 in Phase I/IIa trials in kidney transplant and stroke patients. In addition, the Company has nine partnered small molecule drug discovery programs and other targets under investigation. Seven of these programs are based on chemokine receptors and two are based on integrins. Corporate partnerships accelerate the Company's development and commercialization programs while allowing LeukoSite to build value by focusing on its strengths in discovery and development. The Company is collaborating with Warner-Lambert Company, Roche Bioscience, Kyowa Hakko Kogyo Co., Ltd., Genentech, Inc., Ilex Oncology, Inc. and MorphoSys AG.